Please ensure Javascript is enabled for purposes of website accessibility
Is Alzheimer's Breakthrough Drug Finally Coming?
Bill McEwen updated website photo 2024
By Bill McEwen, News Director
Published 7 years ago on
July 26, 2018

Share

CHICAGO — Hopes are rising again for a drug to alter the course of Alzheimer’s disease after decades of failures. An experimental therapy slowed mental decline by 30 percent in patients who got the highest dose in a mid-stage study, and it removed much of the sticky plaque gumming up their brains, the drug’s makers said Wednesday.
The results have been highly anticipated and have sent the stock of the two companies involved soaring in recent weeks.
The drug from Eisai and Biogen did not meet its main goal in a study of 856 participants, so overall, it was considered a flop. But company officials said that 161 people who got the highest dose every two weeks for 18 months did significantly better than 245 people who were given a dummy treatment.
There are lots of caveats about the work, which was led by company scientists rather than academic researchers and not reviewed by outside experts. The study also was too small to be definitive and the results need to be confirmed with more work, dementia experts said. But they welcomed any glimmer of success after multiple failures.

Cautious Optimism About Drug

“We’re cautiously optimistic,” said Maria Carrillo, chief science officer of the Alzheimer’s Association, whose international conference in Chicago featured the results.
“A 30 percent slowing of decline is something I would want my family member to have,” and the drug’s ability to clear the brain plaques “looks pretty amazing,” she said.
About 50 million people worldwide have dementia, and Alzheimer’s is the most common type. There is no cure— current medicines just ease symptoms. Some previous efforts to develop a drug to slow the disease may have been tried too late, after much damage had already occurred. The new drug aimed sooner, in people with early Alzheimer’s, and the drug works at an earlier step in the formation of the sticky brain plaques.
Study participants were given one of five doses of BAN2401 or a dummy treatment via IV. After one year, the companies said the drug didn’t meet statistical goals. But after 18 months, they saw a benefit in the highest dose group.

New Measurement of Mental Decline

What makes it tricky, though, is that they used a new way to measure mental decline, a scale that combines parts of three other widely used tests. This is the first study to use that measure, and it’s unclear how much of a difference a 30 percent slowing of decline makes — whether it allows someone to continue to bathe or feed himself, for instance.
“It’s intriguing, but these are designs we’re not used to seeing,” and it will require more study for doctors to feel comfortable with this as a measure of success, said one independent expert, Dr. Julie Schneider of Rush University Medical Center in Chicago.
On one traditional measure of thinking skills, those at the highest dose declined 47 percent less than people given a dummy treatment.

High Doses Remove Brain Plaques

Brain scans added evidence that the drug might be effective. All participants had signs of the sticky plaques that are the hallmark of Alzheimer’s at the start of the study, but 81 percent of people on the highest dose saw all signs of them disappear after 18 months, an Eisai official said.
Side effects leading to discontinuation of treatment occurred in 19 percent of those on the high dose and 6 percent of the dummy treatment group. Cases of brain swelling, which have been seen in other treatments targeting the plaques in the brain, occurred in two people in the placebo group and 16 of those in the high dose group.
Other dementia experts were encouraged.
“That’s a very hopeful outcome. It means we may be on the right track,” said another scientist with no role in the work, Dr. Stephen Salloway, neurology chief at Brown University in Providence, Rhode Island.

Not a Cure

Dr. Reisa Sperling, a neurologist at Harvard-affiliated Brigham and Women’s Hospital in Boston, said it’s important to realize that this is not a cure, just possibly a slowing of decline.
“We’re not suddenly returning people back to their pre-Alzheimer’s baseline,” she said.
Dr. Lynn Kramer, chief medical officer of Eisai’s neurology unit, said the companies would talk with regulators about further studies.
Shares of Biogen, based in Cambridge, Massachusetts, and Eisai, based in Tokyo, soared after July 5 when they announced that the drug had slowed the progression of early Alzheimer’s disease for certain patients. Biogen’s stock jumped 19.6 percent in one day, its biggest move in 14 years, and has continued to rise. Eisai rocketed 40 percent in two days.
Biogen stock gyrated in aftermarket trading after the study results were released. After switching between gains and losses several times, it fell 6.5 percent.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Yastrzemski and Chapman Homers Help Giants Rally Past the Brewers

DON'T MISS

Fresno City Council Finally Passes a Tough Smoke Shop Ordinance

DON'T MISS

Fresno Unified Trustee Wittrup Says District Had Stronger Candidates Than Misty Her

DON'T MISS

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

DON'T MISS

Lights, Camera, Board Vote: Fresno Unified’s Carefully Choreographed Production

DON'T MISS

US Farm Agency Withdraws Proposal Aimed at Lowering Salmonella Risks in Poultry

DON'T MISS

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

DON'T MISS

Candi Is the Dandy to Add a Little Sweetness to Your Life

DON'T MISS

How Trump Tariffs Could Upend California Farms, Wine Businesses, and Ports

DON'T MISS

Tulare Man Sentenced to State Prison for DUI Crash That Injured Two Women

UP NEXT

Chicago Bears Great Steve McMichael Dies at 67 After Battle With ALS

UP NEXT

Long Wait Is Over for Cam Ward, Travis Hunter and Other Draft Prospects Joining the NFL

UP NEXT

Golden State’s Jimmy Butler Injured in Game 2 Loss, His Status for Game 3 Unknown

UP NEXT

Jalen Green Makes Eight 3s to Help Rockets Even Series With Warriors

UP NEXT

US Justice Department Directs Investigations Over Gender-Affirming Care

UP NEXT

US Justice Department Cancels Hundreds of Grants for Police, Crime Victims

UP NEXT

Yelich’s 5th Career Slam and Bauers’ 2-Run Homer Power the Brewers to Win Over the Giants

UP NEXT

Happ Hits Game-Ending Single in the 10th as the Cubs Rally Past Dodgers

UP NEXT

Trump: No Plans to Fire Fed Chair Powell, but Wants Lower Rates

UP NEXT

Top Producer at ’60 Minutes’ Quits Amid Trump Lawsuit Pressure

Bill McEwen,
News Director
Bill McEwen is news director and columnist for GV Wire. He joined GV Wire in August 2017 after 37 years at The Fresno Bee. With The Bee, he served as Opinion Editor, City Hall reporter, Metro columnist, sports columnist and sports editor through the years. His work has been frequently honored by the California Newspapers Publishers Association, including authoring first-place editorials in 2015 and 2016. Bill and his wife, Karen, are proud parents of two adult sons, and they have two grandsons. You can contact Bill at 559-492-4031 or at Send an Email

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

11 hours ago

Lights, Camera, Board Vote: Fresno Unified’s Carefully Choreographed Production

12 hours ago

US Farm Agency Withdraws Proposal Aimed at Lowering Salmonella Risks in Poultry

12 hours ago

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

12 hours ago

Candi Is the Dandy to Add a Little Sweetness to Your Life

13 hours ago

How Trump Tariffs Could Upend California Farms, Wine Businesses, and Ports

13 hours ago

Tulare Man Sentenced to State Prison for DUI Crash That Injured Two Women

14 hours ago

Judge Partly Blocks Trump Order Seeking to Overhaul US Elections

15 hours ago

Two From Search Group That Uncovered Mexico’s ‘Ranch of Horror’ Killed

15 hours ago

US Warns States They Could Lose Transportation Funding Over Immigration, DEI Policies

15 hours ago

Yastrzemski and Chapman Homers Help Giants Rally Past the Brewers

SAN FRANCISCO — Mike Yastrzemski and Matt Chapman homered as the San Francisco Giants rallied to beat the Milwaukee Brewers 6-5 on Thursday ...

9 hours ago

9 hours ago

Yastrzemski and Chapman Homers Help Giants Rally Past the Brewers

10 hours ago

Fresno City Council Finally Passes a Tough Smoke Shop Ordinance

11 hours ago

Fresno Unified Trustee Wittrup Says District Had Stronger Candidates Than Misty Her

President Donald Trump delivers remarks during an 'Unleashing American Energy' event at the Department of Energy in Washington, U.S., June 29, 2017. (REUTERS File)
11 hours ago

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

12 hours ago

Lights, Camera, Board Vote: Fresno Unified’s Carefully Choreographed Production

Chickens sit at a poultry farm. March 12, 2025. (REUTERS/Diego Vara/File Photo)
12 hours ago

US Farm Agency Withdraws Proposal Aimed at Lowering Salmonella Risks in Poultry

12 hours ago

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

Candi, GV Wire's Adoptable Cat of the Week
13 hours ago

Candi Is the Dandy to Add a Little Sweetness to Your Life

Help continue the work that gets you the news that matters most.

Search

Send this to a friend